Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326465 | 0.89 | TNKS2 (0.50) | KDM4EHTTTNKS2METAP2GAA | |
| SCHEMBL27379359 | 0.88 | KDM4E (0.42) | KDM4EHTTTNKS2METAP2GAA | |
| SCHEMBL29326363 | 0.88 | TNKS2 (0.50) | KDM4EHTTTNKS2GAATP53 | |
| SCHEMBL29326676 | 0.88 | KDM4E (0.45) | KDM4EHTTTNKS2GAATP53 | |
| SCHEMBL29326311 | 0.84 | KDM4E (0.47) | KDM4EHTTTNKS2GAATP53 | |
| SCHEMBL29326366 | 0.84 | KDM4E (0.47) | KDM4EHTTTNKS2GAATP53 | |
| SCHEMBL29326236 | 0.84 | NPEPPS (0.44) | KDM4EHTTTNKS2GAANPEPPS | |
| SCHEMBL29326224 | 0.84 | NPEPPS (0.48) | KDM4EHTTGAATP53NPEPPS | |
| SCHEMBL29326316 | 0.83 | KDM4E (0.55) | KDM4EHTTTNKS2GAATP53 | |
| SCHEMBL29326437 | 0.83 | KDM4E (0.50) | KDM4EHTTGAATP53NPEPPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | KDM4E 3744/4885HTT 3577/4885TNKS2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.